Masimo Corporation (NASDAQ:MASI) Receives $181.17 Consensus Target Price from Analysts

Masimo Corporation (NASDAQ:MASI) has been given an average recommendation of “Hold” by the nine ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $181.1667.

MASI has been the topic of a number of recent analyst reports. Piper Sandler cut shares of Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price target on the stock. in a report on Tuesday, February 17th. Wells Fargo & Company lowered shares of Masimo from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $190.00 to $180.00 in a research report on Wednesday, February 18th. BTIG Research lowered Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 price objective on shares of Masimo in a research note on Tuesday, February 17th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Monday, December 1st.

Institutional Trading of Masimo

A number of large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in Masimo in the fourth quarter worth $116,000. Pacer Advisors Inc. increased its stake in Masimo by 21.1% in the 4th quarter. Pacer Advisors Inc. now owns 7,360 shares of the medical equipment provider’s stock worth $957,000 after buying an additional 1,280 shares during the period. Virtu Financial LLC bought a new stake in Masimo during the 4th quarter valued at about $258,000. T. Rowe Price Investment Management Inc. boosted its position in Masimo by 9.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,330,158 shares of the medical equipment provider’s stock valued at $303,061,000 after buying an additional 203,395 shares during the period. Finally, Corient Private Wealth LLC grew its stake in Masimo by 1.6% in the 4th quarter. Corient Private Wealth LLC now owns 341,730 shares of the medical equipment provider’s stock worth $44,445,000 after acquiring an additional 5,515 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Trading Up 0.0%

Masimo stock opened at $175.37 on Monday. Masimo has a 12 month low of $125.94 and a 12 month high of $186.27. The business’s fifty day simple moving average is $145.54 and its two-hundred day simple moving average is $144.47. The company has a market capitalization of $9.42 billion, a price-to-earnings ratio of -16.64, a price-to-earnings-growth ratio of 1.78 and a beta of 1.21. The company has a current ratio of 2.49, a quick ratio of 1.92 and a debt-to-equity ratio of 0.72.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.